维普期刊资源整合服务平台（V6.5）

130篇 您的检索式：作者名="Lasho TL"

选中清除导出查看参考文献查看引证文献引用追踪共7页首页上一页第1页下一页末页 /7 跳转

	题名	作者	年代	出处	被引量
1	IDH1 and IDH2 mutation analysis inchronic- and blast-phase my- eloproliferative neoplasms显示文摘	Pardanani A Lasho TL Finke CM	2010	Leukemia2010，24，6：	1
2	Calreticulin mutations and long-term survival in essential thmmboeythemia 显示文摘	Tefferi A Wassie EA Lasho TL	2014	Leukemia2014，28，12：	1
3	JAK2 mutation in essential thrombocythaemia: clinical associations and long- term prognostic relevance显示文摘	Wolanskyj AP Lasho TL Schwager SM	2005	Br J Haematol2005，131，2：	1
4	CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia 显示文摘	Pardanani A Lasho TL Laborde RR	2013	Leukemia2013，27，9：	1
5	CALR vsJAK2 vs MPL-mutated or triple -negative myelofibrosis: clinical, cytogenetic and molecular comparisons显示文摘	Tefferi A Lasho TL	2014	Leukemia2014，28，7：	1
6	CALR vs JAK2 vs MPL- mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons 显示文摘	Tefferi A Lasho TL Finke CM	2014	Leukemia2014，28，7：	1
7	CALR vs JAK2 vs MPL- mutated or triple - negative myeloflbrosis : clinical, cytogenetie andmolecular comparisons 显示文摘	Tefferi A Lasho TL Finke CM	2014	Leukemia2014，28，7：	1
8	SF3BI mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value显示文摘	Patnaik MM Lasho TL Hodnefield JM	2012	Blood2012，119，2：	1
9	Systemic mastocytosis in 342 consecutive adults:survival studies and prognostic factors显示文摘	Lim KH Tefferi A Lasho TL	2009	Blood2009，113，：	1
10	Type 1 vs type 2 calreticulinmutations in primary myelofibrosis: differences in phenotype and prognostic impact 显示文摘	Tefferi A Lasho TL Finke C	2014	Leukemia2014，28，7：	1
11	Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors显示文摘	Lim KH Tefferi A Lasho TL	2009	Blood2009，113，23：	1
12	JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm:assessment of value in a series of 664 consecutive patients显示文摘	Pardanani A Lasho TL Hussein K	2008	Mayo Clin Proc2008，83，：	1
13	CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients 显示文摘	Tefferi A Guglielmelli P Lasho TL	2014	Leukemia2014，28，7：	1
14	LNK mutations in JAK2 mutation- negative erythrocytosis 显示文摘	Lasho TL Pardanani A Tefferi A	2010	N Engl J Med2010，363，12：	1
15	JAK2V617F mutation in essential thrombocy thaemia:clincal associations and long-term prognostic relevance显示文摘	Wolanskyi AP Lasho TL Schwager SM	2005	Br J Haematol2005，131，2：	1
16	JAK2 mutation in essential thrombocythaemia: clinical associations and long- term prognosticrelevance 显示文摘	Wolankkyj AP Lasho TL Schwager SM	2005	Br J Haematol2005，131，2：	1
17	SF3 B I mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value 显示文摘	Patnaik MM Lasho TL Hodnefield 1M et aI	2012	Blood2012，119，2：	1
18	The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia:lineage specificity and clinical correlates显示文摘	Tefferi A Lasho TL Schwager SM	2005	Br J Haematol2005，131，3：	1
19	Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis 显示文摘	Pardanani A Laborde RR Lasho TL	2013	Leukemia2013，27，6：	1
20	CALR and ASXL1 mutations - based molecular prognostication in primary myelofibro- sis: an international study of 570 patients显示文摘	Tefferi A Guglielmelli P Lasho TL	2014	Leukemia2014，28，7：	1

返回顶部每页显示：

共7页首页上一页第1页下一页末页 /7 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示